Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 9.95TCr 36Cr 32Cr 30Cr 27Cr 51Cr 3.41TCr 52Cr 356.14Cr 139.63Cr 1.78TCr 134.96Cr 132.09Cr 5.68TCr P/E 2026 *
9.41x
P/E 2027 * 7.82x
Enterprise Value 9.95TCr 36Cr 32Cr 30Cr 27Cr 51Cr 3.41TCr 52Cr 356.14Cr 139.63Cr 1.78TCr 134.96Cr 132.09Cr 5.68TCr EV / Sales 2026 *
1.45x
EV / Sales 2027 * 1.33x
Free-Float
16.89%
Yield 2026 *
5.77%
Yield 2027 * 6.66%
04/09 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
04/09 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
28/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
25/08 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
25/08 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026, Payable on September 11, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day+0.19%
1 week-1.31%
Current month-0.16%
1 month-0.69%
3 months-12.66%
6 months-20.60%
Current year-19.84%
1 week 309
Extreme 309
315.99
1 month 305
Extreme 305
326.05
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.27
3 years 74
Extreme 74
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-1.31%-27.05%+309.50% 36Cr
+0.43%+6.59%+56.57%+106.64% 1,12000Cr
+0.90%-2.25%+32.26%+63.73% 62TCr
+0.71%+3.24%+24.33%+91.33% 50TCr
-0.13%+5.98%+33.66%+50.18% 37TCr
+0.52%+0.24%+72.13%+40.11% 36TCr
-0.95%+4.70%+19.65%+42.71% 29TCr
-1.98%+3.73%-0.89%+10.43% 26TCr
-0.35%+4.25%+44.74%+52.06% 23TCr
-0.75%+3.32%+27.18%+94.07% 19TCr
Average -0.14%+3.27%+28.26%+86.08% 39.41TCr
Weighted average by Cap. +0.13%+3.83%+39.33%+71.84%

Financials

2026 *2027 *
Net sales 6.88TCr 25Cr 22Cr 20Cr 19Cr 35Cr 2.36TCr 36Cr 246.29Cr 97Cr 1.23TCr 93Cr 91Cr 3.93TCr 7.46TCr 27Cr 24Cr 22Cr 20Cr 38Cr 2.56TCr 39Cr 266.92Cr 104.65Cr 1.33TCr 101.15Cr 99Cr 4.26TCr
Net income 1.05TCr 3.79Cr 3.37Cr 3.12Cr 2.84Cr 5.36Cr 359.8Cr 5.45Cr 38Cr 15Cr 187.76Cr 14Cr 14Cr 598.55Cr 1.24TCr 4.49Cr 3.99Cr 3.7Cr 3.36Cr 6.35Cr 426.02Cr 6.45Cr 44Cr 17Cr 222.31Cr 17Cr 16Cr 708.7Cr
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pakistan Limited
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
16/26/16 PKR 312.45 +0.19% 13,698
15/26/15 PKR 311.85 -0.19% 82,470
14/26/14 PKR 312.44 +0.40% 57,509
13/26/13 PKR 311.19 -0.26% 62,009
12/26/12 PKR 312.00 -1.45% 63,979
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
312.45PKR
Average target price
510.00PKR
Spread / Average Target
+63.23%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GlaxoSmithKline Pakistan Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock